{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:29:58Z","timestamp":1764782998030,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.atherosclerosis.2007.03.001","type":"journal-article","created":{"date-parts":[[2007,4,7]],"date-time":"2007-04-07T07:16:30Z","timestamp":1175930190000},"page":"122-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels"],"prefix":"10.1016","volume":"196","author":[{"given":"Wimon","family":"Phuntuwate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuthamanee","family":"Suthisisang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banhan","family":"Koanantakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preecha","family":"Chaloeiphap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Mackness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Mackness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.0954-6820.1987.tb03356.x","article-title":"Reduced high-density lipoproteins as a risk factor after acute myocardial infarction","volume":"221","author":"Franzen","year":"1987","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"Current concepts: high-density lipoproteins\u2014the clinical implications of recent studies","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.crd.0000097140.29929.8a","article-title":"High-density lipoprotein cholesterol and coronary heart disease","volume":"12","author":"Young","year":"2004","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib4","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2165\/00003495-200363180-00003","article-title":"Low high-density lipoprotein cholesterol physiological background, clinical importance and drug treatment","volume":"63","author":"Hersberger","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0014-5793(91)80962-3","article-title":"Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein","volume":"286","author":"Mackness","year":"1991","journal-title":"FEBS Lett"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0021-9150(93)90183-U","article-title":"Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase","volume":"104","author":"Mackness","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib7","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1172\/JCI118359","article-title":"Protective effect of high-density lipoprotein associated paraoxonase inhibition of the biological activity of minimally oxidized low-density lipoprotein","volume":"96","author":"Watson","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib8","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1161\/01.CIR.101.21.2510","article-title":"Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions PON1 esterase and peroxidase-like activities","volume":"101","author":"Aviram","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/ng0193-73","article-title":"The molecular basis of the human serum paraoxonase activity polymorphism","volume":"3","author":"Humbert","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib10","first-page":"1","article-title":"Modulation of paraoxonase (PON1) activity","author":"Costa","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/CS20040187","article-title":"Genetic and environmental factors modulating serum concentrations and activities of the anti-oxidant enzyme paraoxonase 1","volume":"107","author":"Deakin","year":"2004","journal-title":"Clin Sci"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/01.ATV.19.2.330","article-title":"Serum paraoxonase after myocardial infarction","volume":"19","author":"Ayub","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0021-9150(91)90215-O","article-title":"Serum paraoxonase activity in familial hypercholesterlaemia and insulin-dependent diabetes mellitus","volume":"86","author":"Mackness","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1042\/cs0980355","article-title":"Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy","volume":"98","author":"Mackness","year":"2000","journal-title":"Clin Sci"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib15","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000070954.00271.13","article-title":"Low paraoxonase activity predicts coronary events in the caerphilly prospective study","volume":"107","author":"Mackness","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: veterans affairs high-density Lipoprotein Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib18","doi-asserted-by":"crossref","first-page":"24N","DOI":"10.1016\/S0002-9149(01)02149-X","article-title":"Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism","volume":"88","author":"Fruchart","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1185\/0300799009117017","article-title":"A new formulation of fenofibrate: suprabioavailable tablets","volume":"16","author":"Guichard","year":"2000","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/01.ATV.15.11.1812","article-title":"Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins","volume":"15","author":"Abbott","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.bjp.0701390","article-title":"Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon","volume":"1997","author":"Mackness","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/320600","article-title":"Effects of 5\u2032 regulatory region polymorphisms on paraoxonase-gene (PON1) expression","volume":"68","author":"Brophy","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0021-9150(98)00095-1","article-title":"Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus","volume":"139","author":"Mackness","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib25","doi-asserted-by":"crossref","first-page":"30N","DOI":"10.1016\/S0002-9149(01)02150-6","article-title":"Increasing high-density lipoprotein cholesterol: an update on fenofibrate","volume":"88","author":"Despres","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib26","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1067\/mhj.2002.124833","article-title":"Comparison of the effects of atorvastatin or fenofibrate on non-lipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia","volume":"144","author":"Melenovosky","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(03)00296-X","article-title":"Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles","volume":"170","author":"Wang","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2004.01.033","article-title":"Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis","volume":"174","author":"Koh","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/01.ATV.20.9.2113","article-title":"Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients","volume":"20","author":"Tomas","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00044011-200019040-00005","article-title":"Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patient with hyperlipidaemia","volume":"19","author":"Paragh","year":"2000","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1262-3636(07)70077-0","article-title":"The effects of micronized fenofibrate on paraoxonase activity in patients with coronary heart disease","volume":"29","author":"Paragh","year":"2003","journal-title":"Diab Metab"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-9150(98)00003-3","article-title":"Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer protein, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia","volume":"138","author":"Durrington","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib33","first-page":"83","article-title":"Changes in paraoxonase and apolipoprotein A-I, B, CIII and E in subjects with combined familial hyperlipoproteinaemia treated with ciprofibrate","volume":"26","author":"Turay","year":"2002","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/mol.63.4.945","article-title":"Opposite regulation of the human paraoxonase 1 gene PON1 by fenofibrate and statins","volume":"63","author":"Gouedard","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib35","first-page":"598","article-title":"Molecular basis for the polymorphic forms of human serum paraoxonase\/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes","volume":"52","author":"Adkins","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0021-9150(99)00379-2","article-title":"A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression","volume":"150","author":"Suehiro","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib37","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1210\/jcem.82.7.4096","article-title":"Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus","volume":"82","author":"Odawara","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib38","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1161\/01.ATV.17.12.3565","article-title":"A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese","volume":"17","author":"Zama","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0021-9150(96)05917-5","article-title":"The Gln\/Arg polymorphism of human paraoxonase (PON192) is not related to myocardial infarction in the ECTIM Study","volume":"126","author":"Herrmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1399-0004.1991.tb03096.x","article-title":"Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins","volume":"40","author":"Saha","year":"1991","journal-title":"Clin Genet"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/01.ATV.15.1.89","article-title":"A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate","volume":"15","author":"Hegele","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.03.001_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00008571-200110000-00009","article-title":"Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol","volume":"11","author":"Malin","year":"2001","journal-title":"Pharmacogenetics"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007001396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007001396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:19:57Z","timestamp":1762186797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915007001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0021915007001396"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.03.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}